CalciMedica, Inc. (CALC) Stock

NASDAQ: CALCHealthcare company in the biotechnology industry, based in La Jolla, CA.

CalciMedica stock price chart

CALC interactive chart →

CALC stock quote & key statistics

CalciMedica earnings per share

Income →
Earnings per share

CalciMedica revenue & net income

Income →
RevenueNet income

CalciMedica annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$29.6M-$4.73
FY2024$0-$13.7M-$2.07
FY2023$0-$34.4M-$5.57
FY2022$0-$7.8M-$24.92
FY2021$0-$35.8M-$23.66

Fiscal year ending December 31. Source: company filings via EODHD.

About CalciMedica, Inc.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

CalciMedica stock FAQ

What is the CalciMedica stock ticker symbol?

CalciMedica, Inc. trades on the NASDAQ under the ticker symbol CALC.

What sector and industry is CalciMedica in?

CalciMedica, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does CalciMedica have?

CalciMedica, Inc. has about 15 full-time employees.

What were CalciMedica's revenue and earnings last fiscal year?

CalciMedica reported revenue of $0 and net income of -$29.6M in fiscal 2025, with earnings per share of -$4.73.

When did CalciMedica go public?

CalciMedica stock began trading on September 25, 2020.

Biotechnology stocks

All Healthcare stocks →